Roles of αsynuclein in gastrointestinal microbiome dysbiosisrelated Parkinson's disease progression (Review).
Reads0
Chats0
TLDR
In this article, the abnormal accumulation of α-synuclein (α-syn) in the intestine caused by changes to the gastrointestinal microbiome (GM) caused misfolding and abnormal aggregation of α−syn in the intestines, leading to the formation of eosinophilic Lewis bodies in the cytoplasm and mitochondrial dysfunction in dopaminergic (DA) neurons.Abstract:
Parkinson's disease (PD) is the second most common neurodegenerative disease amongst the middle‑aged and elderly populations. Several studies have confirmed that the microbiota‑gut‑brain axis (MGBA) serves a key role in the pathogenesis of PD. Changes to the gastrointestinal microbiome (GM) cause misfolding and abnormal aggregation of α‑synuclein (α‑syn) in the intestine. Abnormal α‑syn is not eliminated via physiological mechanisms and is transported into the central nervous system (CNS) via the vagus nerve. The abnormal levels of α‑syn aggregate in the substantia nigra pars compacta, not only leading to the formation of eosinophilic Lewis Bodies in the cytoplasm and mitochondrial dysfunction in dopaminergic (DA) neurons, but also leading to the stimulation of an inflammatory response in the microglia. These pathological changes result in an increase in oxidative stress (OS), which triggers nerve cell apoptosis, a characteristic of PD. This increase in OS further oxidizes and intensifies abnormal aggregation of α‑syn, eventually forming a positive feedback loop. The present review discusses the abnormal accumulation of α‑syn in the intestine caused by the GM changes and the increased levels of α‑syn transport to the CNS via the MGBA, resulting in the loss of DA neurons and an increase in the inflammatory response of microglial cells in the brain of patients with PD. In addition, relevant clinical therapeutic strategies for improving the GM and reducing α‑syn accumulation to relieve the symptoms and progression of PD are described.read more
Citations
More filters
Journal ArticleDOI
Are We What We Eat? Impact of Diet on the Gut–Brain Axis in Parkinson’s Disease
TL;DR: The hypothesis that Parkinson’s disease could begin in the gut is supported, with a focus on how food-based therapies might then have an influence on PD and could ameliorate non-motor as well as motor symptoms.
Journal ArticleDOI
Role of enteric glia and microbiota-gut-brain axis in parkinson disease pathogenesis
Júlio César Claudino dos Santos,Micael Porto Portela Lima,Gerly Anne de Castro Brito,Glauce Socorro de Barros Viana +3 more
TL;DR: In this article , the authors discuss how the microbiota-gut-brain axis and environmental influences interact with the immune system to promote a pro-inflammatory state that is involved in the initiation and progression of misfolded α-synuclein proteins and the beginning of the early non-motor symptoms of Parkinson's disease.
Journal ArticleDOI
Neuroprotective Effects of Bifidobacterium breve CCFM1067 in MPTP-Induced Mouse Models of Parkinson’s Disease
Tiantian Li,Chuanqi Chu,Leilei Yu,Qixiao Zhai,Shunhe Wang,Jianxin Zhao,Hao Zhang,Wei Jiong Chen,Fengwei Tian +8 more
TL;DR: In this paper , the effects of probiotic Bifidobacterium breve CCFM1067, administered for 5 weeks in a Parkinson's disease (PD) mouse model, were examined.
Journal ArticleDOI
Bacillus amyloliquifaciens-Supplemented Camel Milk Suppresses Neuroinflammation of Autoimmune Encephalomyelitis in a Mouse Model by Regulating Inflammatory Markers
TL;DR: In this paper , Bacillus amyloliquefaciens-supplemented camel milk (BASY) was used to assess its preventive effect on MS symptoms in a myelin oligodendrocyte glycoprotein (MOG)-immunized C57BL6J mice model.
Journal ArticleDOI
METTL14 is decreased and regulates m6A modification of α‐synuclein in Parkinson's disease
Honghu He,Qinxin Zhang,Jiajia Liao,Jiang Lei,Man Luo,Jian-feng Huang,Mei-Ling Chen,Yuefei Shen,Jing Wang,Pingyi Xu,Yousheng Xiao +10 more
TL;DR: In this article , the role of m6A modification and its underlying mechanism in Parkinson's disease was investigated and the potential of METTL14 as a novel diagnostic biomarker for PD was revealed.
References
More filters
Journal ArticleDOI
Alteration of the fecal microbiota in North-Eastern Han Chinese population with sporadic Parkinson's disease.
TL;DR: The gut microbiota composition of 10 patients with sporadic PD and over 65 age and 10 matched controls was analyzed to explore fecal microbiota compositions in North-eastern Han sporadic PD patients and will provide a foundation to improve the understanding of PD.
Journal ArticleDOI
Lipopolysaccharide from Gut Microbiota Modulates α-Synuclein Aggregation and Alters Its Biological Function.
Dipita Bhattacharyya,Ganesh M. Mohite,Janarthanan Krishnamoorthy,Nilanjan Gayen,Surabhi Mehra,Ambuja Navalkar,Samuel A. Kotler,Bhisma N Ratha,Anirban Ghosh,Rakesh Kumar,Kanchan Garai,Atin K. Mandal,Samir K. Maji,Anirban Bhunia +13 more
TL;DR: Biophysical techniques in conjunction with microscopic images revealed the molecular interaction between lipopolysaccharide and α-synuclein that induce rapid nucleation events and characterizes this heteromolecular interaction associated with an alternative pathway in Parkinson's disease progression.
Journal ArticleDOI
The Link between Gut Dysbiosis and Neuroinflammation in Parkinson's Disease.
TL;DR: Evidence from clinical and basic science implicating microglia activation by gut dysbiosis and how this phenomenon may impact in the symptomatology and progression of PD is explored.
Journal ArticleDOI
T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease.
Gregory P. Williams,David J. Marmion,Aubrey M Schonhoff,Asta Jurkuvenaite,Woong-Jai Won,David G. Standaert,Jeffrey H. Kordower,Ashley S. Harms +7 more
TL;DR: It is suggested that T cell priming and infiltration into the CNS are key mechanisms of disease pathogenesis in MSA, and therapeutics targeting T cells may be disease modifying.
Journal ArticleDOI
Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
Omar M. A. El-Agnaf,Cassia R. Overk,Edward Rockenstein,Michael Mante,Jazmin Florio,Anthony Adame,Nishant N. Vaikath,Nour K. Majbour,Seung-Jae Lee,Changyoun Kim,Eliezer Masliah,Robert A. Rissman,Robert A. Rissman +12 more
TL;DR: This study found that Syn-O1, -O4 and -F1 antibodies were most effective at reducing accumulation of α-syn oligomers in multiple brain regions and at preventing neurodegeneration.